Gerresheimer's Liquidity Gamble: Selling the Crown Jewels to Buy Time

German pharma supplier Gerresheimer sells profitable US business to survive accounting scandal, loan covenant breach, and BaFin investigation, risking future earnings.

The Düsseldorf-based pharmaceutical supplier Gerresheimer is taking drastic action to shore up its strained finances, initiating a retreat from the United States by putting its most profitable business unit up for sale. This fire sale, while providing immediate cash, threatens to permanently erode the company's earnings power in a bid to survive a deepening corporate crisis.

At the heart of the turmoil are systematic accounting errors related to "bill-and-hold" sales agreements for the 2024 financial year. These flaws have triggered a cascade of consequences. Germany's financial regulator, BaFin, is investigating the faulty revenue bookings, while the Auditor Oversight Body (APAS) has opened a professional misconduct procedure against Gerresheimer's auditor, KPMG. The firm had issued an unqualified audit opinion for the 2024 accounts despite the now-confirmed irregularities.

This accounting scandal has created an information blackout with severe repercussions. Because a certified annual report for 2025 was not submitted by the March 31 deadline, Gerresheimer was ejected from the SDAX index on April 10, with its place taken by Shelly Group SE. More critically, the company is currently in breach of its loan covenants due to the missing audited statements. Management is in intense negotiations with its banks to secure deadline extensions, forcing the indefinite postponement of quarterly results and the annual shareholder meeting.

To generate liquidity and appease creditors, Gerresheimer has mandated Morgan Stanley to find a buyer for its lucrative US subsidiary, Centor Inc., a leading provider of packaging systems for prescription medicines. The transaction is slated for completion this year. The unit was last carried on the books at a value of 292 million euros. In a parallel move, the company will shutter its Moulded Glass plant in Chicago Heights by the end of 2026, shifting production to facilities in Italy and India.

The cost of this restructuring will be steep. The company anticipates non-cash impairment charges of 220 to 240 million euros for the 2025 fiscal year, primarily related to technology and development projects at Sensile Medical AG and assets of Gerresheimer Moulded Glass Chicago Inc.

All roads now lead to a single, decisive deadline: June 2026. By that date, Gerresheimer must present a certified financial statement. This document is the mandatory prerequisite for securing long-term extensions of its bank credit lines. The company's current financial forecast for 2026—projecting revenue of 2.3 to 2.4 billion euros with an adjusted EBITDA margin of around 18%—is explicitly conditional on stabilized financing and a positive resolution from BaFin.

Market sentiment reflects the profound uncertainty. The share price recently stood at 17.46 euros, marking a 37% decline since the start of the year and a staggering 73% drop from its 52-week high. With a Relative Strength Index (RSI) of 25.6, the stock is deep in technically oversold territory, though this offers little comfort amid the fundamental crisis. Unconfirmed market speculation about takeover interest from US competitor Silgan Holdings underscores the pervasive nervousness among investors. The pressure for a rapid resolution is immense, making a successful agreement with its banks the only viable bridge to any future.